ASX CODE: IMC

Immuron ASX IMC Travelan North America sales revenue 2019

Immuron’s Travelan anti-diarrhea product drives record revenue in North America

Immuron (ASX: IMC) revealed its full year 2019 revenue in North America has grown more than 50% to reach $1.16 million – driven by...
Immuron ASX IMC US Department of Defense Travelan Shigellosis challenge study Shigella

Immuron reports positive results from Travelan testing, develops anti-dysentery vaccine products

Australian biopharmaceutical company Immuron (ASX: IMC) has reported positive results from a study designed to test the efficacy of Travelan anti-dysentery medication on non-human...
Immuron ASX IMC US Department of Defense gastro infections research Travelan

Immuron and US Department of Defense look to develop silver bullet for gastro infections

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral immunotherapeutics for the treatment of gut...
Immuron ASX IMC colitis IBD irritable bowel syndrome

Immuron takes aim at the rapid growth of autoimmune diseases

Biopharmaceutical company Immuron (ASX: IMC) has hailed its colitis preclinical program at the University of Zürich, Switzerland as a complete success. Immuron is currently developing...
Immuron ASX IMC Travelan sales

Immuron achieves strong sales numbers with Travelan

Microbiome biopharmaceutical company Immuron (ASX: IMC) has revealed encouraging sales numbers in relation to its over-the-counter gastrointestinal and digestive health supplement Travelan. The biotech company...
Immuron ASX IMC positive clinical study results fatty liver disease

Immuron reports positive clinical study results in the fight against fatty liver disease

Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the...
Immuron ASX IMC Travelan US Department of Defense

Immuron’s Travelan successful in US Department of Defense testing

Microbiome biopharmaceutical company Immuron (ASX: IMC) reported its commercially available Travelan had performed well during United States Department of Defense testing, with the product...
Immuron IMC first stage colitis preclinical program

Immuron successfully completes first stage colitis preclinical program

Immuron Limited (ASX: IMC), has successfully completed the first stage of its colitis preclinical program at the University of Zurich, Switzerland, and is preparing to...

RECENT POSTS

STOCK SUMMARY

HOT TOPICS

TRENDING POSTS